D. Kuritzkes

发表

2022 update of the drug resistance mutations in HIV-1.

D. Richman, A. Wensing, F. Ceccherini‐Silberstein, 2022, Topics in antiviral medicine.

Simple filter microchip for rapid separation of plasma and viruses from whole blood

Francoise F Giguel, D. Kuritzkes, Shuqi Wang, 2012, International journal of nanomedicine.

Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate.

Francoise F Giguel, D. Kuritzkes, Shuqi Wang, 2013, Small.

Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence

Alan S. Perelson, Hulin Wu, Song Yu, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Vancomycin-resistant gram-positive bacteria isolated from human sources

D. Kuritzkes, M. Ferraro, K. Ruoff, 1988, Journal of clinical microbiology.

Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens.

D. Kuritzkes, Mohamed S. Draz, M. Kanakasabapathy, 2017, Nanoscale.

Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care

Francoise F Giguel, C. I. Ozdemir, D. Kuritzkes, 2014, Scientific Reports.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

S. Hammer, M. Hirsch, D. Richman, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Update of the drug resistance mutations in HIV-1: December 2010.

D. Richman, H. Günthard, V. Johnson, 2010, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

M. Hughes, M. Hirsch, D. Kuritzkes, 2007, The Journal of infectious diseases.

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

Alyssa J. Porter, M. Zody, M. Lederman, 2014, PloS one.

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

S. Hammer, M. Hirsch, D. Richman, 2000, JAMA.

Update of the drug resistance mutations in HIV-1: 2007.

D. Richman, H. Günthard, V. Johnson, 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo

James Theiler, Eoin Coakley, Bette Korber, 2009, PloS one.

Track A Basic Science

S. Sugden, D. Hazuda, F. Pereyra, 2012, Journal of the International AIDS Society.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.

Savas Tasoglu, Utkan Demirci, Fatih Inci, 2013, ACS nano.

Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva

Emily B Hanhauser, Manoj Kumar Kanakasabapathy, Hadi Shafiee, 2015, Scientific Reports.

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

B Clotet, S. Hammer, M. Hirsch, 1998, JAMA.

What risk of death would people take to be cured of HIV and why? A survey of people living with HIV

Karen A. Scherr, P. Ubel, K. Freedberg, 2019, Journal of virus eradication.

Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin

D. Kuritzkes, R. Price, S. Deeks, 2008, Antiviral therapy.

Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

R. Langer, D. Kuritzkes, O. Farokhzad, 2010, Nanomedicine.

Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.

Brent A. Johnson, J. Nachega, D. Kuritzkes, 2013, AIDS patient care and STDs.

Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics

D. Lauffenburger, F. Pereyra, D. Kuritzkes, 2014, Open forum infectious diseases.

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV

D. Kuritzkes, J. Schapiro, P. Cahn, 2022, HIV medicine.

HIV-1 entry inhibitors: recent development and clinical use.

D. Kuritzkes, T. Henrich, 2013, Current opinion in virology.

Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate

D. Kuritzkes, T. Henrich, A. Tsibris, 2010, Journal of acquired immune deficiency syndromes.

HIV-1 entry inhibitors: an overview

D. Kuritzkes, 2009, Current opinion in HIV and AIDS.

In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1.

R. Schooley, D. Kuritzkes, E. Connick, 1996, The Journal of infectious diseases.

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

John P. Moore, D. Kuritzkes, 2009, Current opinion in HIV and AIDS.

Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19

D. Kuritzkes, S. Erb, S. Quek, 2021, Antimicrobial resistance and infection control.

Emergence of Dual Resistance to Zidovudine and Lamivudine in Clinical HIV-1 Isolates from Patients Receiving Zidovudine/Lamivudine Combination Therapy

D. Kuritzkes, M. Rosandich, Rebekah JA Gass, 1998 .

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

J. Montaner, D. Kuritzkes, S. Walmsley, 2003, The New England journal of medicine.

Virologic Characterization of HIV Type 1 With a Codon 70 Deletion in Reverse Transcriptase

D. Kuritzkes, H. Hatano, Zixin Hu, 2007, Journal of acquired immune deficiency syndromes.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

T. F. Rinke de Wit, T. Hallett, M. Wainberg, 2017, The lancet. HIV.

Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia

Jeffrey N. Martin, D. Kuritzkes, H. Hatano, 2012, Antimicrobial Agents and Chemotherapy.

Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness

D. Kuritzkes, Zixin Hu, 2010, Journal of acquired immune deficiency syndromes.

ART reduces T cell activation and immune exhaustion markers in HIV controllers.

D. Kuritzkes, Xu G. Yu, P. Sax, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia

D. Kuritzkes, D. Bangsberg, Jonathan Z. Li, 2014, AIDS.

Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095

D. Kuritzkes, B. Schackman, A. Krambrink, 2007, Journal of acquired immune deficiency syndromes.

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials

D. Kuritzkes, J. Mellors, R. Bosch, 2016, Journal of acquired immune deficiency syndromes.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

K. Metzner, M. Kozal, R. Paredes, 2011, JAMA.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

M. Hughes, D. Kuritzkes, C. Flexner, 2009, The Journal of infectious diseases.

Monitoring HIV treatment in developing countries

M. Hirsch, D. Kuritzkes, J. Mukherjee, 2006, BMJ : British Medical Journal.

Emerging nanotechnology approaches for HIV / AIDS treatment & prevention Review

Robert Langer, Omid C Farokhzad, Jinjun Shi, 2010 .

Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211)

M. Hughes, D. Kuritzkes, C. Flexner, 2010, Journal of acquired immune deficiency syndromes.

Development of a microfluidic system for measuring HIV-1 viral load

Feng Xu, Utkan Demirci, Altug Akay, 2010, Defense + Commercial Sensing.

Efficient on-chip isolation of HIV subtypes.

Utkan Demirci, Fatih Inci, Umut A Gurkan, 2012, Lab on a chip.

Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options

T. Ndung’u, D. Kuritzkes, J. Reeves, 2011, Journal of acquired immune deficiency syndromes.

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

K. Tashima, D. Kuritzkes, C. Shikuma, 2011, AIDS research and human retroviruses.

Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.

M. Lederman, D. Kuritzkes, J. McCune, 2000, The Journal of infectious diseases.

Clinical features and treatment of infection due to mycobacterium fortuitum/chelonae complex.

D. Kuritzkes, E. McFarland, 1993, Current clinical topics in infectious diseases.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Targeted HIV testing at birth supported by low and predictable mother‐to‐child transmission risk in Botswana

M. Hughes, D. Kuritzkes, S. Lockman, 2018, Journal of the International AIDS Society.

HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States

D. Kuritzkes, J. Currier, S. Cohn, 2016, AIDS and Behavior.

An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes".

D. Kuritzkes, 2012, Archives of internal medicine.

SARS‐CoV‐2 RNA Detection by a Cellphone‐Based Amplification‐Free System with CRISPR/CAS‐Dependent Enzymatic (CASCADE) Assay

D. Kuritzkes, M. Kanakasabapathy, H. Shafiee, 2021, Advanced materials technologies.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

B. Walker, D. Kuritzkes, J. Martinez-Picado, 2019, The lancet. HIV.

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Francoise F Giguel, M. Hughes, D. Kuritzkes, 2008, Journal of Virology.

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

D. Kuritzkes, K. Reimann, W. Powderly, 2004, The Journal of infectious diseases.

A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”?

B. Walker, M. Lederman, D. Kuritzkes, 2016, Pathogens & immunity.

Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30

Emily B Hanhauser, D. Kuritzkes, T. Henrich, 2018, PLoS pathogens.

Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group (ACTG) 5366.

D. Kuritzkes, J. Simoni, E. Scully, 2020, AIDS research and human retroviruses.

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study

Emily B Hanhauser, Francoise F Giguel, P. D. de Bakker, 2014, Open forum infectious diseases.

Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists

John P. Moore, R. Berro, D. Kuritzkes, 2012, Antimicrobial Agents and Chemotherapy.

Use of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB)

D. Kuritzkes, E. Lin, X. Y. Zhang, 1984, Journal of bacteriology.

Use of lac operon fusions to isolate Escherichia coli mutants with altered expression of the fumarate reductase system in response to substrate and respiratory controls.

D. Kuritzkes, E. Lin, F. Ruch, 1979, Biochemical and biophysical research communications.

Escherichia coli mutant with altered respiratory control of the frd operon

D. Kuritzkes, E. Lin, S. Iuchi, 1985, Journal of bacteriology.

UpdateoftheDrugResistanceMutationsinHIV-1: Spring 2008

D. Richman, H. Günthard, V. Johnson, 2008 .

Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.

D. Kuritzkes, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.

D. Kuritzkes, 2005, The Journal of infectious diseases.

Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.

D. Kuritzkes, R. D’Aquila, E. Acosta, 2001, The Journal of infectious diseases.

Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

D. Kuritzkes, S. Swindells, J. Castro, 2013, Journal of acquired immune deficiency syndromes.

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.

M. Lederman, D. Kuritzkes, C. Rinaldo, 2013, The Journal of antimicrobial chemotherapy.

HAART for HIV-1 infection: zeroing in on when to start: comment on "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters".

D. Kuritzkes, 2011, Archives of internal medicine.

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

M. Hughes, M. Hirsch, D. Kuritzkes, 2010, Journal of acquired immune deficiency syndromes.

Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.

D. Kuritzkes, B. Schackman, E. Acosta, 2008, The Journal of infectious diseases.

Adipocyte-Derived Hormone Levels in HIV Lipodystrophy

R. Eckel, D. Kuritzkes, K. Lichtenstein, 2003, Antiviral therapy.

Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa.

D. Kuritzkes, L. Smeaton, H. Sunpath, 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV

M. Lederman, D. Kuritzkes, N. Mehta, 2017, Pathogens & immunity.

Crosstalk between Host Genome and Metabolome among People with HIV in South Africa

Yan V. Sun, D. Kuritzkes, V. Marconi, 2022, Metabolites.

Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals

D. Kuritzkes, C. Katlama, M. Youle, 2004, The Lancet.

Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 &Dgr;32

Emily B Hanhauser, F. Pereyra, Jeffrey N. Martin, 2015, AIDS.

SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses

John P. Moore, Steven Wolinsky, D. Kuritzkes, 2011, PloS one.

Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis

Pardis C Sabeti, Tracey A. Cho, D. Kuritzkes, 2017, Open forum infectious diseases.

Understanding Treatment- Resistant HIV

R. Haubrich, D. Kuritzkes, V. Miller, 2003 .

Clinical significance of drug resistance in HIV‐1 infection

D. Kuritzkes, 1996, AIDS.

Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

D. Kuritzkes, D. Bellgrau, Cara C Wilson, 2001, Nature Medicine.

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1A Randomized, Controlled Equivalence TrialNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

D. Kuritzkes, C. Fichtenbaum, D. Haas, 2014 .

“Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication

Karen A. Scherr, P. Ubel, K. Freedberg, 2020, AIDS and Behavior.

Evolution of coreceptor utilization to escape CCR5 antagonist therapy

M. Mitreva, D. Kuritzkes, T. Henrich, 2016, Virology.

Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.

R. Schooley, D. Kuritzkes, E. Connick, 2001, The Journal of infectious diseases.

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Emily B Hanhauser, D. Kuritzkes, R. Bosch, 2016, The Journal of infectious diseases.

A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV‐1 Reverse Transcriptase Variants

Jiasen Lu, D. Kuritzkes, 2001, Journal of acquired immune deficiency syndromes.

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

B. Walker, D. Kuritzkes, E. Losina, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Second-Line Antiretroviral Therapy: Long-Term Outcomes in South Africa

J. Nachega, D. Kuritzkes, V. Marconi, 2012, Journal of acquired immune deficiency syndromes.

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

Emily B Hanhauser, Daniel I. S. Rosenbloom, R. Siliciano, 2016, bioRxiv.

Enumeration of CD 4 + T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients

Umut A. Gurkan, Utkan Demirci, Umut Atakan Gurkan, 2011 .

Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States

R. Haubrich, D. Kuritzkes, P. Sax, 2021, Open forum infectious diseases.

Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort

R. Haubrich, D. Kuritzkes, P. Sax, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Outcomes after virologic failure of first-line ART in South Africa

D. Kuritzkes, E. Losina, V. Marconi, 2010, AIDS.

Emerging technologies for point-of-care management of HIV infection.

Hadi Shafiee, Utkan Demirci, Fatih Inci, 2015, Annual review of medicine.

Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System

D. Kuritzkes, R. Grant, P. Feorino, 2003, Journal of Clinical Microbiology.

Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis

Rebecca Hoh, Daniel R Kuritzkes, Jeffrey N. Martin, 2006, Journal of acquired immune deficiency syndromes.

Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations

D. Kuritzkes, S. Deeks, R. Ziermann, 2006, Journal of Clinical Microbiology.

Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations

D. Kuritzkes, S. Deeks, R. Ziermann, 2006, Journal of Clinical Microbiology.

Drug resistance in HIV-1.

D. Kuritzkes, 2011, Current Opinion in Virology.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

An update on HIV-1 antiretroviral resistance

D. Kuritzkes, R. Plank, 2006, Current opinion in HIV and AIDS.

Hematopoietic stem cell transplantation for HIV cure.

D. Kuritzkes, 2016, The Journal of clinical investigation.

Early experience with HSCT in HIV-infected patients

D. Kuritzkes, 2016 .

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.

D. Kuritzkes, J. Ritz, T. Henrich, 2018, Blood advances.

HIV-1 subtype as a determinant of disease progression.

D. Kuritzkes, 2008, The Journal of infectious diseases.

Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.

D. Kuritzkes, R. D’Aquila, T. Campbell, 1993, The Journal of infectious diseases.

Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

D. Kuritzkes, J. Bartlett, S. Riddler, 2009, AIDS research and human retroviruses.

Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.

D. Kuritzkes, C. Petropoulos, J. Whitcomb, 2001, The Journal of infectious diseases.

Why cure, why now?

D. Kuritzkes, 2016, Journal of Medical Ethics.

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia

D. Kuritzkes, C. Delaugerre, J. Molina, 2011, AIDS.

Fat distribution is altered in HIV‐infected men without clinical evidence of the HIV lipodystrophy syndrome

R. Eckel, D. Kuritzkes, J. Hamilton, 2003, HIV medicine.

Drug development strategies for salvage therapy: conflicts and solutions.

M. J. van der Laan, D. Kuritzkes, J. Schapiro, 2006, AIDS research and human retroviruses.

Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118)

S. Hammer, D. Kuritzkes, J. Gerber, 2005, Antiviral therapy.

HIV Clinical Trials: Important Concepts and Questions

M. Hughes, D. Kuritzkes, P. Sax, 2005 .

Comparing effectiveness of first‐line antiretroviral therapy between peri‐urban and rural clinics in KwaZulu‐Natal, South Africa

D. Kuritzkes, V. Marconi, Jonathan Z. Li, 2021, HIV medicine.

Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

M. Hughes, K. Tashima, R. Paredes, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial

D. Kuritzkes, D. Ward, R. Wong, 1998, AIDS.

Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement

Emily B Hanhauser, Hadi Shafiee, Utkan Demirci, 2014, Scientific Reports.

Ethical conduct of research in resource-limited settings.

D. Kuritzkes, 2004, The Journal of infectious diseases.

Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child.

R. Schooley, D. Kuritzkes, T. Curiel, 1993, Journal of Infectious Diseases.

Treatment of HIV Infection with a Raltegravir-Based Regimen Increases LDL Levels, but Improves HDL Cholesterol Efflux Capacity

M. Lederman, D. Kuritzkes, N. Mehta, 2017, Antiviral therapy.

A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa

D. Kuritzkes, K. Castro, V. Marconi, 2020, BMC Infectious Diseases.

Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV‐1‐Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy

T. Gingeras, D. Kuritzkes, J. Eron, 2000, Journal of acquired immune deficiency syndromes.

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Clinical pharmacology and therapeutics.

HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug

D. Kuritzkes, T. Henrich, Zixin Hu, 2011, Journal of Virology.

Genotypic tests for determining coreceptor usage of HIV-1.

D. Kuritzkes, 2011, The Journal of infectious diseases.

Tropism testing in the clinical management of HIV-1 infection

D. Kuritzkes, N. Lin, 2009, Current opinion in HIV and AIDS.

Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy

M. Lederman, D. Kuritzkes, N. Mehta, 2020, Translational Medicine Communications.

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

D. Kuritzkes, C. Perno, M. S. St. Clair, 2018, Journal of acquired immune deficiency syndromes.

Drug Resistance Working Group. AIDS Clinical Trials Group Virology Committee virus type 1 drug resistance mutation. The reaction to detect a human immunodeficiency sequence-specific PCR and ligase detection Interlaboratory comparison of

R. Shafer, D. Kuritzkes, M. Winters, 2013 .

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

F. Brun-Vézinet, D. Kuritzkes, A. Zolopa, 2010, AIDS.

Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group

R. Shafer, D. Kuritzkes, A. Iversen, 1996, Journal of clinical microbiology.

Mother-to-Child HIV Transmission with in utero Dolutegravir vs. Efavirenz in Botswana.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, Journal of acquired immune deficiency syndromes.

Impact of pre-existing drug resistance on risk of virological failure in South Africa.

R. Paredes, D. Kuritzkes, Katherine Rodriguez, 2021, The Journal of antimicrobial chemotherapy.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

A. Wensing, D. Kuritzkes, D. Pillay, 2018, The lancet. HIV.

Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures.

D. Kuritzkes, H. Kessler, J. Bremer, 1999, JAMA.

Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation

Emily B Hanhauser, A. LaCasce, D. Kuritzkes, 2018, PloS one.

Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

D. Kuritzkes, R. Gandhi, F. Venter, 2007, The Journal of infectious diseases.

Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana: Preliminary Results from a Large Randomized Clinical Trial

D. Kuritzkes, V. DeGruttola, M. Essex, 2007, Journal of acquired immune deficiency syndromes.

Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy

M. Lederman, D. Kuritzkes, R. Bosch, 2004, AIDS.

Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images

D. Kuritzkes, M. Kanakasabapathy, H. Shafiee, 2021, Nature Biomedical Engineering.

Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone.

Anish Vasan, Prudhvi Thirumalaraju, Aparna Sreeram, 2018, ACS nano.

Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy

V. Johnson, D. Kuritzkes, M. Fischl, 2007, Antiviral therapy.

Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response

M. Hughes, M. Hirsch, V. Johnson, 1997, Annals of Internal Medicine.

Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile

D. Kuritzkes, Xu G. Yu, M. Lichterfeld, 2019, Science Translational Medicine.

Human immunodeficiency virus.

R. Siliciano, D. Richman, D. Kuritzkes, 2009 .

Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group.

D. Kuritzkes, C. Farthing, R. Steigbigel, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

M. Lederman, D. Kuritzkes, J. Leonard, 1998, The Journal of infectious diseases.

Infection of the retina by human immunodeficiency virus type I.

R. Schooley, M. Hirsch, D. Kuritzkes, 1987, The New England journal of medicine.

HIV viral load markers in clinical practice

D. R. Kuritzkes, D. Richman, P. Volberding, 1996, Nature Medicine.

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients

D. Kuritzkes, J. Eron, J. Eron, 1996, AIDS.

Viral Load Kinetics of SARS-CoV-2 In Hospitalized Individuals with COVID-19

Elizabeth, Francoise F Giguel, A. Perelson, 2021 .

Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019

Francoise F Giguel, N. Hacohen, A. Perelson, 2021, Open forum infectious diseases.

Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

D. Kuritzkes, J. Eron, R. MacArthur, 1995 .

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

S. Hammer, M. Hirsch, D. Richman, 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

J. Tolson, D. Kuritzkes, K. Squires, 2002, The Journal of infectious diseases.

Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction.

D. Kuritzkes, 2004, The Journal of infectious diseases.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group

V. Johnson, D. Kuritzkes, R. D’Aquila, 1993, Antimicrobial Agents and Chemotherapy.

Patients Infected with CRF07_BC Have Significantly Lower Viral Loads than Patients with HIV-1 Subtype B: Mechanism and Impact on Disease Progression

D. Kuritzkes, Chia-Jui Yang, Zixin Hu, 2014, PloS one.

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

D. Kuritzkes, A. Krambrink, C. Shikuma, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

D. Kuritzkes, A. Caliendo, R. D’Aquila, 1999, The Journal of infectious diseases.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

C. Pettinelli, I. Marschner, V. Johnson, 1999, AIDS.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Victoria A Johnson, Daniel R Kuritzkes, Françoise Brun-Vézinet, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance mutations in HIV-1.

R. Shafer, D. Richman, V. Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection

J. Montaner, M. Wainberg, D. Kuritzkes, 2005, Antiviral therapy.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Roger Paredes, Victoria A Johnson, Daniel R Kuritzkes, 2010, The Journal of infectious diseases.

Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates

D. Kuritzkes, P. Reichelderfer, S. Fiscus, 1994, Journal of clinical microbiology.

Update of the Drug Resistance Mutations in HIV-1: December 2008

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2008 .

High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998–2004

R. Paredes, D. Kuritzkes, R. Tuomala, 2007, AIDS.

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

M. Lederman, D. Kuritzkes, H. Kessler, 2000, AIDS.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Edward P Acosta, Victoria A Johnson, Daniel R Kuritzkes, 2008, The Journal of infectious diseases.

Extending antiretroviral therapy to resource-poor settings: implications for drug resistance

D. Kuritzkes, 2004, AIDS.

Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

J. Halter, K. Schmader, D. Kuritzkes, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Workshop on HIV Infection and Aging: What Is Known and Future Research Directions

J. Halter, K. Schmader, D. Kuritzkes, 2008 .

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Steven C Johnson, Steven C. Johnson, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical implications of HIV-1 minority variants.

D. Kuritzkes, Jonathan Z. Li, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Huldrych F Günthard, Deenan Pillay, Victoria A Johnson, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Evolution of resistance in paediatric patients with failure on antiretroviral therapy

K. Freedberg, D. Kuritzkes, R. Wood, 2012, Journal of the International AIDS Society.

T Cell Subset Enumeration and Weekend HIV Clinics: Reliable Performance of CD4 Cell Counts after 3 Days

D. Kuritzkes, T. Henrich, H. Ribaudo, 2010 .

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.

M. Lederman, D. Kuritzkes, H. Kessler, 2000, The Journal of infectious diseases.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Update of the drug resistance mutations in HIV-1: Fall 2006.

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa

D. Kuritzkes, V. Marconi, R. Gandhi, 2012, PloS one.

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine

M. Lederman, D. Kuritzkes, J. Mellors, 2013, PloS one.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

International AIDS Society global scientific strategy: towards an HIV cure 2016

Richard Jefferys, David Margolis, Jintanat Ananworanich, 2016, Nature Medicine.

Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095

D. Kuritzkes, B. Schackman, E. Acosta, 2005, Antiviral therapy.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

David W. Haas, Todd T. Brown, Daniel R. Kuritzkes, 2014, Annals of internal medicine.

Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1

D. Kuritzkes, Zixin Hu, 2011, Journal of Virology.

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

D. Kuritzkes, V. Marconi, M. Gordon, 2012, AIDS.

The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations

D. Kuritzkes, M. Götte, Luis R Miranda, 2005, Antimicrobial Agents and Chemotherapy.

Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation

V. Johnson, D. Kuritzkes, J. Bartlett, 2004, Journal of acquired immune deficiency syndromes.

Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases

R. Haubrich, J. Fellay, A. Telenti, 2011, HIV clinical trials.

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

K. Freedberg, D. Kuritzkes, E. Losina, 2012, PloS one.

The Best Approach to Reintroducing Tuberculosis Treatment after Hepatotoxicity Is Still

D. Kuritzkes, R. Gulick, J. Schouten, 2010 .

Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.

D. Schillinger, D. Kuritzkes, S. Deeks, 2005, AIDS.

Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency

Ingrid A. Beck, K. Metzner, V. Johnson, 2006, Journal of Clinical Microbiology.

Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens.

D. Richman, V. Johnson, D. Kuritzkes, 2000, AIDS research and human retroviruses.

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

D. R. Kuritzkes, Y. Cao, D. Kuritzkes, 1998, Antimicrobial Agents and Chemotherapy.

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen

M. Lederman, D. Kuritzkes, Heather A Baird, 2005, AIDS research and therapy.

In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA

Daniel R. Kuritzkes, Mario Stevenson, D. Kuritzkes, 2005, Journal of Virology.

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Michael D Healy, Kelsey K. Finn, David A. Drew, 2020, Nature Communications.

Human immunodeficiency virus type 1 protease inhibitors.

D. Kuritzkes, D R Kuritzkes, C K McDonald, 1997, Archives of internal medicine.

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

M. Wainberg, D. Kuritzkes, D. Pillay, 2017, The Journal of infectious diseases.

Chemokine antagonists as therapeutics: focus on HIV-1.

D. Kuritzkes, A. Tsibris, Athe Tsibris, 2007, Annual review of medicine.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study

R. Siliciano, D. Richman, D. Kuritzkes, 2017, PLoS medicine.

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

M. Lederman, D. Kuritzkes, J. Mellors, 2015, AIDS.

DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics

Anish Vasan, Manoj Kumar Kanakasabapathy, Aparna Sreeram, 2018, Nature Communications.

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration

Daniel R Kuritzkes, Ruy M Ribeiro, Alan S Perelson, 2017, PLoS pathogens.

Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

R. Haubrich, D. Kuritzkes, B. Taiwo, 2011, The Journal of infectious diseases.

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure.

Steven C. Johnson, D. Kuritzkes, R. R. Ramey, 1998, The Journal of infectious diseases.

High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay

Emily B Hanhauser, D. Kuritzkes, U. Demirci, 2017, EBioMedicine.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370

V. Johnson, D. Kuritzkes, M. Chesney, 2001, Antiviral therapy.

MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study

M. Lederman, D. Kuritzkes, R. Kim, 2003, Journal of acquired immune deficiency syndromes.

Quantum dot-based HIV capture and imaging in a microfluidic channel.

Utkan Demirci, Yun-Gon Kim, Sangjun Moon, 2009, Biosensors & bioelectronics.

Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning.

Manoj Kumar Kanakasabapathy, Prudhvi Thirumalaraju, Xu G Yu, 2020, ACS nano.

Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.

Sebastien Gallien, Jonathan Z Li, Daniel R Kuritzkes, 2012, Journal of virological methods.

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

Emily B Hanhauser, M. Altfeld, D. Kuritzkes, 2014, Annals of Internal Medicine.

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

M. Carrington, B. Walker, R. Schooley, 2011, The Journal of infectious diseases.

A fossil record of zidovudine resistance in transmitted isolates of HIV-1

D. Kuritzkes, 2001, Proceedings of the National Academy of Sciences of the United States of America.

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

R. Schooley, M. Lederman, D. Kuritzkes, 2010, The Journal of infectious diseases.

A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128

David W. Haas, Douglas D. Richman, Margaret A. Matula, 2003, HIV clinical trials.

Virologic and regimen termination surrogate end points in AIDS clinical trials.

S. Hammer, D. Kuritzkes, P. Gilbert, 2001, JAMA.

Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells

R. Schooley, D. Kuritzkes, R. Pomerantz, 2000 .

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals

V. Johnson, D. Kuritzkes, J. Bartlett, 1997, AIDS.

Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy

D. Richman, H. Günthard, V. Johnson, 2000, AIDS.

Immunological and Neurometabolite Changes associated with switch from Efavirenz to an Integrase Inhibitor.

Monica L. Bennett, E. Stern, D. Kuritzkes, 2019, Journal of acquired immune deficiency syndromes.

What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection

D. Kuritzkes, D. Zewdie, J. Lange, 2004, AIDS.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine

Jeffrey N. Martin, R. Paredes, D. Kuritzkes, 2008, Journal of Virology.

Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.

Marc A Suchard, Rebecca Hoh, Daniel R Kuritzkes, 2006, AIDS research and human retroviruses.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption

M. Carrington, D. Kuritzkes, J. Mellors, 2017, Pathogens & immunity.

Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

M. Carrington, B. Walker, R. Schooley, 2012, PloS one.

Rapid, label-free CD4 testing using a smartphone compatible device.

Manoj Kumar Kanakasabapathy, Vinish Yogesh, Mohammadali Safavieh, 2017, Lab on a chip.

Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Sikhulile Moyo, Daniel R Kuritzkes, Shahin Lockman, 2012, Virology.

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants

D. Kuritzkes, S. Lockman, Xueling Wu, 2016, EBioMedicine.

Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study

M. Carrington, R. Schooley, M. Lederman, 2014, AIDS (London).

Errors in Celia Farber's March 2006 article in Harper's Magazine

D. Kuritzkes, J. Safrit, E. Glaser, 2006 .

Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.

R A Betensky, S. Hammer, I. Marschner, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Effect of the Q207D Mutation in HIV Type 1 Reverse Transcriptase on Zidovudine Susceptibility and Replicative Fitness

Daniel R Kuritzkes, D. Kuritzkes, J. Whitcomb, 2005, Journal of acquired immune deficiency syndromes.

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

Emily B Hanhauser, Emily Hanhauser, Daniel I. S. Rosenbloom, 2016, PLoS pathogens.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers

M. Lederman, D. Kuritzkes, Xu G. Yu, 2018, The Journal of clinical investigation.

Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA

P. Volberding, D. Kuritzkes, D. Skiest, 2018, Journal of Virology.

Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.

A. LaCasce, D. Kuritzkes, T. Henrich, 2013, The Journal of infectious diseases.

In vivo analysis of Fas/FasL interactions in HIV-infected patients.

M. Lederman, D. Kuritzkes, H. Kessler, 1998, The Journal of clinical investigation.

Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL

Brian R Wood, D. Kuritzkes, T. Henrich, 2012, PloS one.

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance

Soo-Yon Rhee, Paul Sandstrom, Deenan Pillay, 2007, AIDS.

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy

J. Kahn, D. Richman, C. Crumpacker, 1996 .

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

M. Lederman, D. Kuritzkes, J. Leonard, 2000, The Journal of infectious diseases.

Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Resistance in Pediatric Patients Experiencing Virologic Failure With First-line and Second-line Antiretroviral Therapy

K. Freedberg, D. Kuritzkes, L. Bekker, 2013, The Pediatric infectious disease journal.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

M. Lederman, D. Kuritzkes, C. Flexner, 2013, The Journal of infectious diseases.

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

N. Ford, J. D. da Silva, A. Wensing, 2020, The lancet. HIV.

HIV resistance: frequency, testing, mechanisms.

D. Kuritzkes, 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

D. Kuritzkes, E. Acosta, B. Taiwo, 2011, AIDS.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

K. Tashima, D. Kuritzkes, D. Clifford, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life.

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2020, AIDS.

Immune correlates of HIV-1 reservoir cell decline in early-treated infants

D. Kuritzkes, Xu G. Yu, M. Lichterfeld, 2022, Cell reports.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana

D. Kuritzkes, M. Lichterfeld, Zixin Hu, 2021, AIDS.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

K. Metzner, M. Kozal, R. Paredes, 2013, The Journal of infectious diseases.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

M. Kozal, R. Paredes, D. Kuritzkes, 2012, AIDS.

The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential.

R. Walensky, D. Kuritzkes, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease

Ryung S. Kim, M. Lederman, D. Kuritzkes, 2002, AIDS.

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

Michael I. Jordan, S. Delany-Moretlwe, R. Paredes, 2023, The lancet. HIV.

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing

R. Paredes, D. Kuritzkes, V. Marconi, 2016, AIDS.

Rate of Thymidine Analogue Resistance Mutation Accumulation With Zidovudine- or Stavudine-Based Regimens

V. Johnson, D. Kuritzkes, R. Bassett, 2004, Journal of acquired immune deficiency syndromes.

Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

D. Richman, C. Crumpacker, V. Johnson, 1995, Annals of Internal Medicine.

Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells.

M. Lederman, D. Kuritzkes, B. Levine, 1999, Clinical immunology.

Prevalence and Clinical Associations of CXCR4-Using HIV-1 Among Treatment-Naive Subtype C-Infected Women in Botswana

D. Kuritzkes, S. Lockman, M. Essex, 2011, Journal of acquired immune deficiency syndromes.

Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1

D. Kuritzkes, H. Hatano, Zixin Hu, 2006, Journal of Virology.

Drug Resistance Testing: Time to be Used in Clinical Practice?

D. Kuritzkes, 2001 .

Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment

D. Richman, C. Crumpacker, V. Johnson, 1995 .

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

M. Lederman, D. Kuritzkes, J. Leonard, 1999, The Journal of infectious diseases.

In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children.

R. Schooley, D. Kuritzkes, E. McFarland, 1998, Journal of immunology.

Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance

Hulin Wu, Edward P Acosta, Daniel R Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.

R. Beroukhim, D. Kuritzkes, S. Lockman, 2010, Journal of virological methods.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Eoin Coakley, Robert Gross, Wayne Greaves, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy

R. Paredes, D. Kuritzkes, R. Tuomala, 2010, AIDS.

Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.

G. Grunwald, R. Eckel, D. Kuritzkes, 2003, Metabolism: clinical and experimental.

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

Emily B Hanhauser, Daniel I. S. Rosenbloom, R. Siliciano, 2017, PLoS pathogens.

Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA

D. Kuritzkes, J. Martinez-Picado, T. Burdo, 2023, Journal of virus eradication.

HIV‐1 proviral landscape characterization varies by pipeline analysis

D. Kuritzkes, A. Tsibris, Olivia Roberts-Sano, 2021, Journal of the International AIDS Society.

Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy

Emily B Hanhauser, A. LaCasce, D. Kuritzkes, 2017, The Journal of infectious diseases.

Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?

D. Kuritzkes, M. Caskey, 2022, Clinical Infectious Diseases.

Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns

Victor DeGruttola, Vincent Calvez, Maurizio Zazzi, 2004, Antiviral therapy.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

K. Tashima, D. Kuritzkes, C. Shikuma, 2007, Journal of acquired immune deficiency syndromes.

Determination of RNA structural diversity and its role in HIV-1 RNA splicing

Matthew D. Edwards, P. Bieniasz, D. Kuritzkes, 2020, Nature.

Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.

D. Kuritzkes, D. Haas, R. Bosch, 2004, The Journal of infectious diseases.

Lines from HIV-1-Infected Children In Vitro Effects of IL-12 on HIV-1-Specific CTL

R. Schooley, D. Kuritzkes, E. McFarland, 2017 .

Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics

Emily B Hanhauser, Utkan Demirci, Fatih Inci, 2015, Proceedings of the National Academy of Sciences.

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

B. Walker, R. Schooley, M. Hirsch, 2000, Journal of Infectious Diseases.

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Annals of Internal Medicine.

Pyomyositis due to group C streptococci in a patient with AIDS.

D. Kuritzkes, A. Nitta, 1991, Reviews of infectious diseases.

Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice.

D. Kuritzkes, I. Chen, Q. Li, 1995, Virology.

COVID-19 and HIV infection co-pandemics and their impact: a review of the literature

D. Kuritzkes, K. Ruxrungtham, S. Gatechompol, 2021, AIDS Research and Therapy.

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

M. Lederman, D. Kuritzkes, H. Kessler, 2003, The Journal of infectious diseases.

HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.

David A. Fleming, D. Kuritzkes, M. Saag, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Challenges in clinical trial design for HIV-1 cure research

D. Kuritzkes, N. Eyal, 2013, The Lancet.

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

J. Karn, D. Kuritzkes, K. Squires, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance mutations in HIV-1.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Associations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa

D. Kuritzkes, V. Marconi, Q. Hui, 2022, medRxiv.

Integrating microfluidics and lensless imaging for point-of-care testing

Ali Khademhosseini, Utkan Demirci, Hasan Onur Keles, 2009, 2009 IEEE 35th Annual Northeast Bioengineering Conference.

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

D. Kuritzkes, J. Jacobson, E. Dejesus, 2008, Antimicrobial Agents and Chemotherapy.

Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine

Samantha MaWhinney, Daniel R. Kuritzkes, D. Kuritzkes, 2002, Antimicrobial Agents and Chemotherapy.

Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.

T. Gingeras, D. Kuritzkes, J. Eron, 2000 .

Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.

D. Richman, H. Günthard, V. Johnson, 1999, The Journal of infectious diseases.

Accuracy of the TRUGENE HIV-1 Genotyping Kit

V. Johnson, D. Kuritzkes, R. Grant, 2003, Journal of Clinical Microbiology.

Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.

M. Lederman, D. Kuritzkes, H. Kessler, 2001, AIDS research and human retroviruses.

Role of Baseline pol Genotype in HIV-1 Fitness Evolution.

M. Lederman, D. Kuritzkes, G. Vanham, 2003, Journal of acquired immune deficiency syndromes.

9 Ribaudo

D. Kuritzkes, B. Schackman, E. Acosta, 2006 .

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

D. Kuritzkes, R. Leavitt, L. Na, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics

Kamyar Mehrabi Kochehbyoki, D. Kuritzkes, Mohamed S. Draz, 2018, Nature Communications.

Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions

M. Hughes, D. Kuritzkes, C. Flexner, 2009, Journal of Clinical Microbiology.

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

R. Shafer, D. Richman, V. Johnson, 1998, Journal of Virological Methods.

Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children.

D. Kuritzkes, E. McFarland, S. MaWhinney, 2002, The Journal of infectious diseases.

Assessing resistance costs of antiretroviral therapies via measures of future drug options.

Victor DeGruttola, Hongyu Jiang, David Katzenstein, 2003, The Journal of infectious diseases.

Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility

D. Kuritzkes, A. Ducatman, M. Galanek, 1990, Applied and environmental microbiology.

Detached ciliary tufts mistaken for peritoneal parasites: a warning.

D. Kuritzkes, D. Bell, G. Dickersin, 1988, Reviews of infectious diseases.

Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures

R. Paredes, D. Kuritzkes, Z. Su, 2012, Journal of Virology.

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure

Thomas Greenough, Daniel R. Kuritzkes, Mario Stevenson, 2011, PLoS pathogens.

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeﬁciency Virus Type 1 Subtype C-Infected Subject (cid:1) †

D. Kuritzkes, C. Flexner, Z. Su, 2008 .

Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors

D. Kuritzkes, Zixin Hu, 2014, Journal of Virology.

Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first‐line therapy in South Africa: a case–control cohort study

D. Kuritzkes, V. Marconi, I. Ofotokun, 2021, Journal of the International AIDS Society.

Three classes of Escherichia coli mutants selected for aerobic expression of fumarate reductase

D. Kuritzkes, E. Lin, S. Iuchi, 1986, Journal of bacteriology.

Update of the drug resistance mutations in HIV-1: 2004.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Preventing and managing antiretroviral drug resistance.

Daniel R Kuritzkes, D. Kuritzkes, 2004, AIDS patient care and STDs.

Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

D. Kuritzkes, J. Schapiro, C. Boucher, 2011, Antiviral therapy.

Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)

Michael Greenberg, Prakash Sista, Daniel R. Kuritzkes, 2004, Journal of Virology.

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

J. Kahn, D. Richman, C. Crumpacker, 1995, The Journal of infectious diseases.

HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.

M. Lederman, D. Kuritzkes, H. Kessler, 1999, AIDS.

Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.

F. Pereyra, R. Plenge, D. Kuritzkes, 2010, The Journal of infectious diseases.

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome

R. Eckel, D. Kuritzkes, A. Scherzinger, 2001, AIDS.

A Plea for Justice for Jailed Medical Workers

A. Trkola, R. Schooley, M. Lederman, 2006, Science.

Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment

Marc A. Suchard, Steven G. Deeks, Christina M. R. Kitchen, 2009, Comput. Stat. Data Anal..

A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.

D. Kuritzkes, Jing Lu, 2001 .

Preventing and Managing Resistance in the Clinical Setting

D. Kuritzkes, 2003, Journal of acquired immune deficiency syndromes.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

B. Walker, R. Schooley, S. Little, 2018, The Journal of infectious diseases.

A graphene-modified cellulose paper microchip for HIV detection

Mohammadali Safavieh, Hadi Shafiee, Daniel R. Kuritzkes, 2015, Sensing Technologies + Applications.

Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets

Hadi Shafiee, Naside Gozde Durmus, Utkan Demirci, 2015, Scientific Reports.

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)

A. Perelson, D. Kuritzkes, J. Mellors, 2015, AIDS.

Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy

M. Peluso, D. Kuritzkes, P. Sax, 2020, The Journal of Infectious Diseases.

Phase 1 study of combination therapy with L-697,661 and zidovudine

R. Schooley, J. Phair, J. Kahn, 1996 .

Bamlanivimab for Prevention of COVID-19.

D. Kuritzkes, 2021, JAMA.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

D. Kuritzkes, K. Squires, B. Schackman, 2007, AIDS.

Hematopoietic cell transplantation and HIV cure: where we are and what next?

D. Kuritzkes, S. Glynn, N. Cook, 2013, Blood.

next? Hematopoietic cell transplantation and HIV cure: where we are and what

D. Kuritzkes, S. Glynn, N. Cook, 2013 .

Small differences in CD4+ T-cell production may go unnoticed.

M. Lederman, D. Kuritzkes, H. Kessler, 1999, AIDS.

Rapid automated cell quantification on HIV microfluidic devices.

Utkan Demirci, Richard L. Lin, Fahim Manzur, 2009, Lab on a chip.

Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial

D. Kuritzkes, R. Bosch, H. Ribaudo, 2000, AIDS.

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection

E. Rosenberg, S. Little, D. Kuritzkes, 2010, PLoS ONE.

Update of the Drug Resistance Mutations in HIV-1: 2005.

Amalio Telenti, Victoria A Johnson, Francoise Brun-Vezinet, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa

D. Kuritzkes, V. Marconi, R. Gandhi, 2013, PLoS ONE.

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy

M. Lederman, D. Kuritzkes, S. Sieg, 2015, PloS one.

Viral and Host Mediators of Non-Suppressible HIV-1 Viremia

A. Engelman, M. Lederman, D. Kuritzkes, 2023, medRxiv : the preprint server for health sciences.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

J. Montaner, B. Clotet, D. Kuritzkes, 2007, AIDS patient care and STDs.

Altered Viral Fitness of HIV‐1 Following Failure of Protease Inhibitor‐Based Therapy

M. Lederman, D. Kuritzkes, H. Valdez, 2000, Journal of acquired immune deficiency syndromes.

Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase

D. Richman, V. Johnson, D. Kuritzkes, 2000, Journal of Clinical Microbiology.

Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.

M. Lederman, D. Kuritzkes, H. Kessler, 1999, AIDS research and human retroviruses.

Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.

D. Kuritzkes, T. Henrich, H. Ribaudo, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Enumeration of CD4+ T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients

Umut A. Gurkan, Utkan Demirci, Umut Atakan Gurkan, 2011, PloS one.

Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men.

M. Altfeld, D. Kuritzkes, R. Bosch, 2016, The Journal of infectious diseases.

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Mark Holodniy, Robert W Shafer, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

R. Paredes, D. Kuritzkes, V. Marconi, 2007, Journal of virological methods.

Interleukin-2: trials and tribulations.

D. Kuritzkes, 2009, The Journal of infectious diseases.

High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection.

D. Kuritzkes, B. Conway, D. Luckey, 1994, The Journal of infectious diseases.

Syncytium formation by recombinant HTLV-II envelope glycoprotein.

D. Kuritzkes, I. Chen, Q. Li, 1996, Virology.

Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol.

D. Richman, H. Günthard, V. Johnson, 1999, Virology.

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

D. Richman, V. Johnson, D. Kuritzkes, 2000, The Journal of infectious diseases.

HIV-1–Infected Antiretroviral-Treated Patients With Prolonged Partial Viral Suppression: Clinical, Virologic, and Immunologic Course

D. Kuritzkes, H. Kessler, J. Bremer, 2003, Journal of acquired immune deficiency syndromes.

A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115

K. Tashima, D. Kuritzkes, J. Bartlett, 2007, Antiviral therapy.

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370

C. Pettinelli, I. Marschner, V. Johnson, 2000, AIDS.

Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIV

D. Kuritzkes, V. Marconi, P. Anderson, 2023, Open forum infectious diseases.

Cardiovascular risk factors and antiretroviral therapy.

D. Kuritzkes, J. Currier, 2003, The New England journal of medicine.

When more is less.

D. Kuritzkes, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide

Sebastian Bonhoeffer, Rebecca Hoh, Roger Paredes, 2008, Journal of acquired immune deficiency syndromes.

Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

D. Kuritzkes, B. Belanger, J. Kowalczyk, 2023, Future Virology.

Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana

D. Kuritzkes, M. Lichterfeld, S. Lockman, 2023, Science Translational Medicine.

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV

K. F. Moseley, D. Kuritzkes, R. Bosch, 2021, Journal of acquired immune deficiency syndromes.

The Future of HIV Treatment

M. Hirsch, D. Kuritzkes, M. Hirsch, 2012, Journal of acquired immune deficiency syndromes.

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.

Wei Huang, Rebecca Hoh, Torsten B Neilands, 2007, The Journal of infectious diseases.

Least among equals.

D. Kuritzkes, I. Sanne, J. Hakim, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lensless imaging for point-of-care testing

Utkan Demirci, Hasan Onur Keles, Yun-Gon Kim, 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Nanoplasmonic biosensing platform for multiple pathogen detection

F. Inci, O. Tokel, S. Wang, 2013, 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII).

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

D. Kuritzkes, K. Squires, C. Shikuma, 2007, The Journal of infectious diseases.

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.

D. Kuritzkes, J. Schapiro, J. Polli, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Progress in HIV vaccine research: an outsider's view

D. Kuritzkes, 2012 .

Update of the drug resistance mutations in HIV-1: 2004.

D. Richman, A. Telenti, V. Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Escherichia coli MutantwithAltered Respiratory Control ofthe frdOperon

D. Kuritzkes, E. Lin, S. Iuchi, 1985 .

Mycobacterium avium complex

W. Schaffner, D. Kuritzkes, P. Densen, 2020, Definitions.

Update of the Drug Resistance Mutations in HIV-1: 2005.

D. Richman, A. Telenti, V. Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Update of the drug resistance mutations in HIV-1: December 2009.

D. Richman, V. Johnson, B. Clotet, 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Erratum: Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol (Virology (1999) 259:1 (154-165))

D. Richman, V. Johnson, D. Kuritzkes, 1999 .

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

R. Paredes, V. Johnson, D. Kuritzkes, 2010, The Journal of infectious diseases.

Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel

S. Hammer, D. Richman, V. Johnson, 2022 .

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

D. Kuritzkes, E. Acosta, B. Taiwo, 2011, AIDS.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

K. Metzner, M. Kozal, R. Paredes, 2013, The Journal of infectious diseases.

A comparison of three initial antiretroviral AIDS regimens.

D. Kuritzkes, H. Ribaudo, R. Gulick, 2007, The New England journal of medicine.

Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection

J. Montaner, M. Wainberg, D. Kuritzkes, 2005, Antiviral therapy.

Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

R. Langer, D. Kuritzkes, O. Farokhzad, 2010, Nanomedicine.

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

John P. Moore, D. Kuritzkes, 2009, Current opinion in HIV and AIDS.

Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care

C. I. Ozdemir, D. Kuritzkes, Shuqi Wang, 2014, Scientific Reports.

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Emily B Hanhauser, D. Kuritzkes, R. Bosch, 2016, The Journal of infectious diseases.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

D. Kuritzkes, P. Goulder, J. Ananworanich, 2019 .

Hematopoietic cell transplantation and HIV cure: where we are and what next?

D. Kuritzkes, S. Glynn, N. Cook, 2013, Blood.

Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

D. Kuritzkes, R. Gandhi, F. Venter, 2007, The Journal of infectious diseases.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T Cell Counts but Have Minimal Effects on Viral Load

Alan S. Perelson, Libin Rong, Steven G. Deeks, 2010, PLoS Comput. Biol..

Viral and host mediators of non-suppressible HIV-1 viremia

D. Kuritzkes, S. Deeks, G. Gaiha, 2023, Nature medicine.

ThreeClasses ofEscherichia coli Mutants Selected forAerobic Expression ofFumarate Reductase

D. Kuritzkes, E. Lin, S. Iuchi, 1986 .

Approaching the asymptote.

D. Kuritzkes, 2022, The lancet. HIV.

Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

D. Kuritzkes, B. Belanger, J. Kowalczyk, 2023, Future virology.

Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia

D. Kuritzkes, R. Bosch, B. Taiwo, 2015, Antiviral therapy.

Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.

Emily B Hanhauser, S. Al-Jumaah, D. Kuritzkes, 2014, AIDS.

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing

R. Paredes, D. Kuritzkes, V. Marconi, 2016, AIDS.